SINGAPORE: A first-of-its-kind partnership between Singapore and the UK will allow patients in both countries to benefit sooner from major medical advances, the Health Sciences Authority (HSA) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) said in a joint statement on Friday (Dec 12).
The launch of the regulatory innovation corridor aims to speed up patient access to breakthrough therapies in high-impact areas such as cancer, dementia, obesity, rare diseases and advanced diagnostics.
This will be done without compromising safety, while strengthening both countries’ roles as global hubs for life science investment, HSA and MHRA said.
